Testing for Doxorubicin Cardiotoxicity

B. Hoefling, J. Zaehringer, H. D. Bolte, Michael R. Bristow, John P. Wexler, M. Donald Blaufox, Leonard M. Freeman, Jonathan Alexander, Harvey J. Berger, Barry L. Zaret, I. Craig Henderson, Emil Frei

Research output: Contribution to journalLetter

3 Scopus citations

Abstract

To the Editor: The February 8 issue of the Journal contained an article by Alexander et al.1 and an editorial by Henderson and Frei2 on the cardiotoxicity of doxorubicin. Both the article and the editorial concluded that sensitive measurements of myocardial function could be used as criteria for discontinuation of doxorubicin treatment. We do agree that even low doses of doxorubicin can produce changes in myocardial function, as shown previously by Friedman et al.,3 Stein et al.4 and our own unpublished results. At doses of about 200 mg per square meter, we found changes in myocardial function in five of.

Original languageEnglish (US)
Pages (from-to)1392-1394
Number of pages3
JournalNew England Journal of Medicine
Volume300
Issue number24
DOIs
Publication statusPublished - Jun 14 1979

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hoefling, B., Zaehringer, J., Bolte, H. D., Bristow, M. R., Wexler, J. P., Blaufox, M. D., ... Frei, E. (1979). Testing for Doxorubicin Cardiotoxicity. New England Journal of Medicine, 300(24), 1392-1394. https://doi.org/10.1056/NEJM197906143002412